Drugs biosimilar strangers are brilliant for Italian cancer patients, or, at minimum half of them. An established fact for clinical practice, for specialists and the “insiders”, but not for them, for those times which could use it. According to estimates, approximately 52 says of Italian cancer patients have not at all heard of biosimilar drugs, does not know the key qualities and has not at all proposed using them.

The lack of piece of information and knowledge when it comes to this kind of medication, goes even further: 6 out of 10 patients not called if the molecules in question are already accessible in the Bel Paese, 46% does not know its possible side effects and merely 15% for complete lack of knowledge approximately it, willing to tried, alter their therapy based on organic drugs.

The puzzling picture is the result of the initial national survey on cancer patients sponsored by the Foundation of the organization of Medical Oncology, Aiming cooperation with the Since the Society of Nephrology, the Honeycomb, the Italian Federation of Voluntary organizations in Oncology el AIMAC, the Italian association for cancer patients, relatives and friends, presented in current days in Rome.

Involved 356 patients and 9 ill out of 10 that permit the usefulness to point out clearly on the packaging of drugs and prescriptions the kind of drug, organic or biosimilar.

“Patients insist answers and are documenting. The critical level for us is not biosimilar yes or no biosimilar: patients insist clear rules by Parliament, Guidelines by scientific societies and monitoring by clinicians to ever have drugs efficient, secure and probably cheaper “noted Francesco De Lorenzo, President and Honeycomb AIMAC.